Skip to main content
CRMD
NASDAQ Life Sciences

Wiseek Filing Insight

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
4
Price
$7.48
Mkt Cap
$586.642M
52W Low
$6.125
52W High
$17.43
Market data snapshot near publication time

check_boxKey Events

  • No key events were highlighted for this filing.

auto_awesomeAnalysis

No analysis available.

At the time of this filing, CRMD was trading at $7.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $586.6M. The 52-week trading range was $6.13 to $17.43. This filing was assessed with an importance score of 4 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CRMD - Latest Insights

CRMD
Apr 29, 2026, 4:16 PM EDT
Filing Type: DEF 14A
Importance Score:
7
CorMedix Finalizes Annual Meeting Proposals, Seeks Shareholder Vote on Key Governance Changes and Preferred Stock Amendment Ratification
Sentiment: Neutral
View Wiseek Article
CRMD
Apr 27, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
CorMedix Announces Positive Phase III Results for REZZAYO, Meeting Primary Endpoint for Fungal Prophylaxis
Sentiment: Positive
View Wiseek Article
CRMD
Apr 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
CorMedix's REZZAYO Phase III Trial Hits Primary Endpoint for Fungal Prophylaxis, Targets $2B Market Expansion
Sentiment: Positive
View Wiseek Article
CRMD
Apr 17, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
7
CorMedix Seeks Shareholder Approval for Key Governance Changes, Including Ratification of Past Preferred Stock Amendments and Officer Liability Limits
Sentiment: Neutral
View Wiseek Article
CRMD
Mar 06, 2026, 5:07 PM EST
Filing Type: 8-K
Importance Score:
8
CorMedix Clarifies FY27 DefenCath Sales Guidance Upward After Earnings Call Misstatement
Sentiment: Positive
View Wiseek Article
CRMD
Mar 05, 2026, 8:32 AM EST
Filing Type: 10-K
Importance Score:
9
CorMedix Reports Transformational 2025 with $163M Net Income, Driven by Melinta Acquisition and DefenCath Growth
Sentiment: Positive
View Wiseek Article
CRMD
Mar 05, 2026, 7:47 AM EST
Filing Type: 8-K
Importance Score:
8
CorMedix Reports Strong Q4 & Full-Year 2025 Results, Reiterates 2026 Guidance
Sentiment: Positive
View Wiseek Article
CRMD
Mar 05, 2026, 7:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
CorMedix Reaffirms FY26 Revenue Guidance at $300M-$320M
Sentiment: Neutral
View Wiseek Article
CRMD
Jan 08, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
8
CorMedix Reports Strong 2025 Results But Warns of Significant DefenCath Reimbursement Decline in H2 2026
Sentiment: Negative
View Wiseek Article